This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Gilead Sciences, Inc.. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: The Innovative Contributions of Derek M Dalton in Pharmaceutical Science
Introduction: Derek M Dalton is an accomplished inventor based in Berkeley, CA, who has made significant strides in the field of pharmaceutical sciences. With a total of two patents to his name, Dalton's work primarily focuses on novel solid forms of FXR agonists, which hold potential for the treatment of various medical conditions.
Latest Patents: Dalton's recent patents revolve around the development of solid forms of FXR agonists. The disclosures detail not only the novel solid forms but also encompass pharmaceutical compositions that include one or more of these solid forms. Moreover, the patents outline methods for utilizing these solid forms in the treatment of conditions mediated by FXR, as well as strategies for obtaining such solid forms.
Career Highlights: Dalton is currently affiliated with Gilead Sciences, Inc., a prominent company in the biopharmaceutical field. His innovative research and development work contribute to enhancing therapeutic options and improving patient outcomes.
Collaborations: Throughout his career, Dalton has collaborated with notable colleagues such as Peter C Fung and Nolan Griggs. These collaborations reflect a strong teamwork ethos within the research environment, paving the way for further advancements in pharmaceutical inventions.
Conclusion: Derek M Dalton's contributions to the field of pharmaceuticals through his innovative patents exemplify the role of inventors in advancing medical science. His work not only addresses urgent clinical needs but also inspires future research in the realm of drug development and treatment methodologies.